The substance which shows choleretic effect


(57) Abstract:

The invention relates to medicine. The essence of the invention lies in the fact that offer potassium salt of glutamic acid as a substance exhibiting choleretic activity. 8 table.

The invention relates to a means to stimulate the physiological functions of the organism, in particular bile secretion, and can be further used in clinical practice.

In recent years in clinical practice in place a number of cholagogue, among which there are tools that stimulate bile production and synthesis of bile salts (hollow) in the liver (the so-called true haeretici) and drugs that increase bile secretion due to only the water component (hydrocholoric). Typical representatives of the latter are the sodium salicylate and its derivatives, preparations, Valerian, ginseng, and many mineral water.

The action of hydropolitical limited influence on the diffusion process of choleresis. They do not increase cholatocholesterol factor and are therefore not fully choleretic agents.

To choleretic means, in logol, holenzim and holesin;

synthetic drugs: vicodin, oxygenated, Cigalon, ibota, salts and esters of salicylic acid and other

drugs of vegetable origin, obtained from sandy immortelle, Bupleurum, corn silk, peppermint, tansy, wild rose and other plants (for example golosas).

However, most known drugs or insufficient, such as cholelithiasis and golosas, or limited usable, for example the sodium salt of dehydrocholic acid, due to accumulation in the body of sodium, or the drug allohol because they evoke long-term use side effects.

The aim of the invention is to develop effective cholagogue with broad pharmacological action.

This goal is achieved by the fact that as a cholagogue apply potassium salt of glutamic acid in doses of 50 to 500 mg per 1 kg of body weight.

Potassium salt of glutamic acid, a natural metabolite of the human body contributes to the concentration in the body potassium is the main intracellular ion, which plays an important role in maintenance of homeostasis, actively especta potassium salt of glutamic acid (synonyms: potassium glutamate, kaputa), previously used in a mixture with monomagnesium salt of the same acid, became possible as a result of established pronounced pharmacological activity of Kalutara resulted in strengthening both the diffusion and secretory processes jelcheobrazovanie liver, stimulating the process of helatoobrazutee and excretion of bilirubin and cholesterol in the bile. The described action is found in the research conducted on animals.

Part of the preparation examples 1 to 3, wt. potassium 22; glutamic acid 78.

P R I m e R 1. Studies performed on 32 passported rats male 6 8 months 10 adults 12 months. The study drugs were administered once daily orally.

All animals were divided into following groups:

1. Treated with saline control group.

2. Kaguta at a dose of 500 mg/kg for 14 days.

3. Kaguta at a dose of 500 mg/kg for 52 days.

4. Kaguta dose of 50 mg/kg for 52 days.


the influence of Kalutara on the intensity of bile secretion (results are presented in table. 1);

the influence of Kalutara on the secretion of bile acids (see table. 2);

influence carlosm. table. 4).

In accordance with the above table. 1 the results of the experiments the intensity of bile secretion in animals treated with kaputa, significantly higher than that in control animals.

As evidenced by the results of the experiments, kaputa has a marked stimulating effect on the secretion of Khalatov: under the influence of the drug at a dose of 50 mg/kg and 500 mg/kg in the vast majority of the time portions concentration of Khalatov increased.

There is a clear stimulating effect on the excretion of cholesterol in the bile.

P R I m m e R 2. Comparative studies choleretic action of Kalutara and allohol. As is well known in medical practice, drug allohol, which along with other ingredients include dry bile of animals, causes an increase in bile secretion, increase the content of bile acids.

The results are shown in table. 5, 6, 7, 8.

As follows from the data of experiments kaputa has more pronounced stimulating effect on the secretion of bile, than allohol when approximately equal to other parameters.

P R I m e R 3. The drug was tested for toxicity. Acute toxicity was determined on white mice-female 9.4 g/kg

When intraabdominal administration LD50to 1.9 g/kg

Therefore, the drug has very low toxicity.

Thus, the claimed as bile substances, potassium glutamate has a pronounced pharmacological activity and can be recommended in the future to widespread clinical practice.

The use of potassium salt of glutamic acid as a substance exhibiting choleretic effect.


Same patents:
The invention relates to medicine, in particular for experimental and clinical therapy, and can be used for adaptogenic effects on the body of a person in extreme conditions or undergoing severe disease

The invention relates to new chemical compound, namely glutamate ethyl ester amben

(I) with antiviral activity that involves its use in medical practice

The invention relates to medicine, more specifically concerns a new drug anti-stress, stress-protective and neuroprotective actions

The invention relates to medicine, in particular to pharmacology and gastroenterology
Bronchodilatory // 2024255
The invention relates to medicine, in particular to pulmonology and pharmacology

The invention relates to medicine, namely to addiction

The invention relates to medicine

The invention relates to the field of medicine

FIELD: medicine, narcology.

SUBSTANCE: one should detect satisfaction insufficiency syndrome due to performing genetic analysis by the presence of, at least, one of the genes coding the exchange of neuromediators being the constituents of human satisfaction system. One should compensate satisfaction insufficiency due to performing, at least, one complex of physical exercises. Moreover, in case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture in patient one should apply the complex of physical exercises including those to provide sedative effect, and in case of availability of pathological gene allele of dopamine-beta-hydroxylase protein one should apply the complex of physical exercises including those that induce an activating effect. In case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture one should apply additional food biologically active additives based upon amino acids being the precursors of neuromediators, such as taurine, D-, L-phenylalanine in combination with 5-hydroxytryptophan, hypericin and vitamin B6, and in case of pathological gene allele of dopamine-beta-hydroxylase protein one should additionally apply food biologically active additives based upon amino acids being the precursors of neuromediators, such as: taurine, tyrosine and/or dimethylaminoethanol, lecithin and group B-vitamins. The present innovation enables to take into account pathological disease mechanism.

EFFECT: higher efficiency of prophylaxis.

14 cl, 5 ex

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to compounds designated for applying in photochemotherapy or diagnosis and indicated compounds represent 5-aminolevulinic acid aryl-substituted esters, their derivatives or pharmaceutically acceptable salts. In particular, invention provides preparing compounds of the general formula (I): R

N-CH2COCH2CH2CO-OR1 wherein R1 represents aryl-substituted C1-alkyl group, preferably C1-alkyl group substituted with non-heteroaromatic aryl wherein indicated group aryl is substituted group, and especially preferable this radical is substituted with one or more alkyl groups (for examples, (C1-C2)-alkyl), alkoxy- (for example, methoxy-) groups, fluorine, chlorine atoms, nitro- or trifluoromethyl groups; R2 being each of that can be similar or different represents hydrogen atom or alkoxycarbonyloxy-; indicated alkyl group is broken optionally with one or more groups: -O-, -NR3-, -S- or -PR3- wherein R3 represents hydrogen atom or (C1-C6)-alkyl group, and their salts for applying in diagnosis and photochemotherapy of injures and disorders of internal and external surfaces of body, and products and sets for realization of this invention also.

EFFECT: valuable medicinal properties of compounds.

18 cl, 17 dwg, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out analysis of clinical manifestations in patients having satisfaction deficiency syndrome. Clinical manifestations like obsessive compulsive disorders occurring, physical training exercises acting upon visceral organs as a result of abdominal wall muscle and inferior and superior small pelvis diaphragm muscle contraction. Clinical manifestations like irritation and aggressiveness being observed, physical training exercises like slow diaphragm-type breathing with deep muscle relaxation or alternating hyperventilation and deep diaphragm-type breathing are to be done. Clinical manifestations like hyperactivity taking place, physical dynamic exercises causing activating action are done in combination with slow deep breathing. Clinical manifestations like emotional disorders being observed, physical training exercises causing sedative action are applied. The exercises are based on alternating muscle and tendon extension and following relaxation. Dietetic low hydrocarbon content nutrition is additionally applied with one of the following diets: low hydrocarbon content diet having animal proteins and saturated with fat, or vegetarian diet having mainly vegetable proteins, moderate hydrocarbon content and large amount of vegetable fibers, or ketogenic diet being protein-and-fat diet containing large amount of fat with fatty acids like triglycerides of chain having not more than 12 carbomers.

EFFECT: enhanced effectiveness of prophylaxis and correction procedures.

11 cl

FIELD: cosmetic industry.

SUBSTANCE: the present innovation deals with preparations to fix, strengthen, restructure, restore or stabilize keratin fibers, especially damaged fibers. For this purpose one should apply creatine, creatinine and/or their salts to provide improves glare, volume or combing capacity of one's hair, as well. Earlier these preparations had been known as hair moisturizers.

EFFECT: higher efficiency of application.

12 cl, 9 ex

FIELD: medicine.

SUBSTANCE: preparation is a crushed and UV-radiation activated β-(3-indolyl)-α-aminocapronic acid obtained by treating dry initial preparation (native aminocapronic acid) crushed to 1-5 mcm large particles with UV-radiation during 12-18 h to the moment the substance decomposition starts. Method involves crushing dry substance of β-(3-indolyl)-α-aminocapronic acid by means of vibration mill with 1500-3000 oscillations per min to 1-5 mcm large particles, activating the crushed product by exposing it to UV-radiation of 250-280 nm wavelength during 12-18 h to the moment the initial substance decomposition starts. The moment is determined by 3-5% large initial mass loss.

EFFECT: enhanced effectiveness of the preparation with no adverse side effects.

6 cl, 3 tbl

FIELD: medicine, dermatology.

SUBSTANCE: one should apply an applicator onto affected parts of skin that contains 5-aminolevulinic acid at concentration of 5-20%. After keeping and removing the applicator it is necessary to irradiate with light at wave length being 630 ± 10 nm and energy density of 10-1200 J/sq. cm. Control should be carried out due to evaluating the concentration of photosensitizer at affected parts of skin due to fixing fluorescence ranges at all basic stages of photodynamic therapy. The method enables to adjust skin relief and achieve scars' whitening and their regression.

EFFECT: higher efficiency of therapy and control.

6 cl, 2 dwg, 3 ex

FIELD: medicine, gynecology, anesthesiology.

SUBSTANCE: invention concerns to a method for carrying out the anesthesiology assistance for woman in childbirth with accompanying bronchial asthma. Method involves administration of atropine, dimedrol, analgin and clophelin. Method involves additional intravenous administration of transamine for 5-7 min. Transamine is administrated in doses 12-14 and 15-17 mg/kg in woman in childbirth with body mass 75 kg and above and 74 kg and less, respectively. Method provides enhancing quality and safety of anesthesia in this class of woman in childbirth.

EFFECT: improved assistance method.

7 tbl, 4 ex

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention relates, in particular, to a composition for interaction of ligands wherein the composition comprises a noncovalent associate of multiple separate conjugates being each of that comprises a head group and a tail group wherein tail groups of conjugates form hydrophobic aggregate. Conjugates are mobile within the associate and in the presence of ligand at least two head groups are places by a method corresponding to the epitope formation that is able to interact with ligand stronger as compared with each separate head group. Invention provides applying conjugates in combinatory approach for detecting effective combinations to induce the desirable interaction in binding in receptor-specific treatment of patients.

EFFECT: valuable properties of epitopes.

31 cl, 2 dwg, 4 ex

FIELD: medicine, pharmacy.

SUBSTANCE: physiologically acceptable sodium salt is dissolved in purified apyrogenic water in the concentration 5-10 g/100 ml and colloidal substance of polymeric nature is added at temperature of solution 40-70C at stirring up to disappearance of polymer solid phase from the surface solution. Solution is stirred for 30-60 min and then subjected for high-temperature treatment at 90-100°C for 15-30 min and successive filtration through micro- and sterilizing filters of pores diameters 0.8 and/or 0.45 and then 0.22 mcm, respectively, and in gradual increasing the pressure value from 0.5 to 3.0 atm and final packaging. Invention provides preparing microimpurity-free hypertonic colloidal solution that is stable in storage and effective in using. Invention can be used in methods for preparing preparations used in reanimatology, intensive therapy and in emergency medicine.

EFFECT: improved preparing method, valuable medicinal properties of preparation.

8 cl, 3 ex